GlassScriptPhysician profile
Joel Kertznus
NPI 1487639308
$66,590.88
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $2,860 · 2021: $11K · 2022: $6,953 · 2023: $6,944 · 2024: $3,880 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $5,054 · Consulting Fee: $1,935 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,500.00 |
| Food and Beverage | $5,053.69 |
| Consulting Fee | $1,935.00 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,539.39 | 2019-2025 | |
| Allergan, INC. | $12,516.42 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11,315.83 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $2,242.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $816.49 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $648.10 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $609.74 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $506.90 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $489.27 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $436.34 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $385.60 | 2019-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $312.20 | 2024-2025 | Omvoh |
| Genzyme Corporation | $243.73 | 2023-2025 | |
| Redhill Biopharma INC. | $199.76 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ipsen Biopharmaceuticals, INC | $197.37 | 2024-2025 | Iqirvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $168.20 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $139.70 | 2019-2024 | Suflave, Sutab |
| Daiichi Sankyo INC. | $113.90 | 2021-2022 | |
| Alfasigma USA, INC. | $109.35 | 2020-2022 | |
| Pfizer INC. | $106.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $76.00 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $61.75 | 2024-2025 | Zenpep |
| Vivus LLC | $53.23 | 2023-2025 | Qsymia, Pancreaze |
| Ironwood Pharmaceuticals, INC | $52.61 | 2019-2022 | |
| Organon LLC | $43.68 | 2024-2025 | Hadlima |
| Exact Sciences Corporation | $38.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shire North American Group INC | $37.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $33.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.76 | 2024 | Dupixent |
| Boston Scientific Corporation | $19.68 | 2020 | |
| Novo Nordisk INC | $18.66 | 2025 | Wegovy |
| Axonics, INC. | $17.65 | 2023 | Axonics |
| Nestle Healthcare Nutrition INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Kertznus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.